To verify the involvement of the HSP90AA1/PI3K/AKT signaling pathway as an important metabolic‐related molecular mechanism involved in hUC‐MSCs therapy aimed at improving the pro‐inflammatory microenvironment of SLE, we conducted animal experiments. Here, AKT1 is linked to systemic lupus erythematosus.